FORM PTO 1449 (modified)			Atty. Dock X-16115	Atty. Docket No. X-16115			Serial No		
INFORMA	TION I	DISCLOSURE CITATION	1	First Appli	icant		•		
IN AN AP	PLICAT	ΓΙΟΝ		ALLEN		rdon			
				Filing Date					
				US Nat'l F		plicable)	1		
		<u>T</u>	J.S. F	PATENT DO	CUME	<u>NTS</u>			
Examiner	Cite	Document Number	Publication Date			Name of Patentee or		Pages, Columns, Lines,	
Initials*	als* No. 1 Number-Kind Code ² (if known)		MM-DD-YY	MM-DD-YYYY Applican		of Cited Document	Where Relevant Pages or Relevant Figures		
								Appear	
	AA	US 2,265,890	05-05-1981			Holden, et al			
	AB	US 5,698,766	12-16-1997			Julius, et al			
	AD	05 5,070,700	12-10-1997			Junus, et ai			
		FOR	EIG	N PATENT	DOCU	MENTS			
Examiner	Cite	Foreign Patent Document				Patentee or		T [€]	
Initials*	No.1	Country Code ³ -Number ⁴⁻		Publication Date		t of Cited iment		Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Kind Code5 (if known)		MM-DD-YYYY			Figures App		
	BA	WO 93/04686 A	03-3	18-1993					
	DD	WO 02/02015 A	02	10 1002					
	BB	WO 93/03015 A	02	18-1993					
	BC	WO 02/074746 A1	09-26-2002						
	BD	WO 03/006466	01-2	23-2003					
	BE	EP 285 287 A2	05.1	10.1988					
	BE	EF 263 267 A2	V 3.1	10.1966					
		NON PAT	TENT	Γ LITERAT	HRE DO	CHME	NTS		
Examiner	Cite							the item	T ⁶
Initials*	No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.						1
	CA	Kilpatrick, et al., "Th	Kilpatrick, et al., "The alpha 2-adreneceptor antagonist SK & F 104078 has high						
		affinity for 5-HT1A and 5-HT2 receptors European Journal of Pharmacology", 166(2)							
		315-18 Coden							
	CB		DATABASE WPI- Section Ch, Week 200274, Derwent Publications LTD., London, GB; Class B02, AN 2002-691852 XP002328506						
	CC		Teacott, et al, "Eating disorder and epilepsy in mice lacking 5-HT2 _C serotonin						
			receptors" Nature, Vol 374, 542-546, 1995						
	CD Upton, et al, "Studies on the role of 5-HT2 _C and 5-HT2 _B receptors in regulating								
	generalized seizure threshold in rodents" <u>European J. O Pharmacology</u> , 359, 33-40 (1998)								
		(1770)							

Examiner	Date Considered	
Signature		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to their Information Office; U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Atty. Docket No. X-16115	Serial No		
		First Applicant ALLEN John Gordon			
		Filing Date US Nat'l Entry (if applicable)	Group		
	NON PATENT I	ITERATURE DOCUMEN	<u>rs</u>		
CE	Vickers, et al, "Oral administration of the 5-HT2 _C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia" Psychopharmacology, 167: 274-280 (2003)				
CF	Martin, et al, "Influence of the 5-HT2 _C receptor antagonist, SB-242084, in tests of anxiety" Pharmacology Biochemistry and Behavior: 71:615-625 (2002)				
CG	Chou-Green, et al, "Compulsive behavior in the 5-HT2 _C receptor knockout mouse" Physiology & Behavior, 78, 641-649 (2003)				
СН	CH Frank, et al, "Sleep and Sleep Homeostasis in Mice Lacking the 5-HT2 _C Receptor" Neuropsychopharmacology, 27:5, 869-873 (2002)				
CI	CI Leysen, et al, "Ligands for the 5-HT2 _C receptor as potential Antidepressants and Anxiolytics" Trends In Drug Research II, 49-61 (1998)				
Cl	CJ Fitzgerald, et al., "Chapter 3: 5-HT2 _C Receptor Modulators: Progress in Development of New CNS Medicines: Annual Reports in Medicinal Chemistry 37, 21, 2002				

Examiner	Date Considered	
Signature		

SEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Finformation Office; U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<u>PATENT APPLICATION</u> IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: ALLEN John Gordon

For: 6-SUBSTITUTED2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES

AS 5-HT2C RECEPTOR AGONISTS

Docket No.: X16115

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner, together with copies of PTO-892 forms submitted to Applicants by Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

/ R. Craig Tucker/ Attorney for Applicants Registration No. 45,165 Phone: 317-433-9829

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288 July 18, 2006